Keymed Biosciences Announces 2026 H1 Results and Business Updates
CHENGDU, China, Aug. 21, 2026 /PRNewswire/ -- On August 19, 2026, Keymed Biosciences (HKEX: 02162) announced its interim results for the six months ended June 30, 2026, with total revenue of RMB617 million. Core product Kangyueda generated sales of RMB393 million, up 132% YoY, supported by a nearly 5...